$IMUX
Immunic Inc

2017 Q2 Form 10-Q Financial Statement

#000128077617000029 Filed on May 09, 2017

View on sec.gov

Income Statement

Concept 2017 Q2 2017 Q1 2016 Q1
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.720M $3.060M $2.800M
YoY Change 1.12% 9.29% -8.5%
% of Gross Profit
Research & Development $9.834M $9.628M $6.857M
YoY Change 43.39% 40.41% -41.66%
% of Gross Profit
Depreciation & Amortization $229.0K $335.0K $494.0K
YoY Change -53.27% -32.19% 68.03%
% of Gross Profit
Operating Expenses $12.55M $12.69M $9.656M
YoY Change 31.46% 31.39% -34.83%
Operating Profit -$12.55M -$12.69M -$9.656M
YoY Change 31.46% 31.39% -34.83%
Interest Expense $170.0K $100.0K $60.00K
YoY Change 112.5% 66.67% 500.0%
% of Operating Profit
Other Income/Expense, Net $142.0K $85.00K $67.00K
YoY Change 82.05% 26.87% 13.56%
Pretax Income -$12.41M -$12.60M -$9.590M
YoY Change 31.05% 31.39% -35.03%
Income Tax
% Of Pretax Income
Net Earnings -$12.41M -$12.60M -$9.589M
YoY Change 31.04% 31.42% -35.03%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$11.71M -$15.37M -$12.62M
COMMON SHARES
Basic Shares Outstanding 42.21M shares 32.14M shares 30.47M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2017 Q2 2017 Q1 2016 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $76.20M $86.60M $77.90M
YoY Change 3.53% 11.17% -11.78%
Cash & Equivalents $76.15M $86.64M $77.88M
Short-Term Investments
Other Short-Term Assets $1.900M $1.700M $1.300M
YoY Change 5.56% 30.77% -43.48%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $78.06M $88.30M $79.24M
YoY Change 3.48% 11.44% -12.56%
LONG-TERM ASSETS
Property, Plant & Equipment $2.430M $2.489M $3.428M
YoY Change -19.38% -27.39% -16.55%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $182.0K $156.0K $253.0K
YoY Change 0.0% -38.34% 27.78%
Total Long-Term Assets $2.612M $2.645M $3.681M
YoY Change -18.27% -28.14% -14.51%
TOTAL ASSETS
Total Short-Term Assets $78.06M $88.30M $79.24M
Total Long-Term Assets $2.612M $2.645M $3.681M
Total Assets $80.68M $90.95M $82.92M
YoY Change 2.6% 9.68% -12.65%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.076M $1.308M $885.0K
YoY Change 21.31% 47.8% -21.54%
Accrued Expenses $6.147M $5.085M $3.788M
YoY Change 78.74% 34.24% -60.5%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $7.292M $6.450M $4.816M
YoY Change 63.02% 33.93% -56.0%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $0.00 $100.0K $100.0K
YoY Change 0.0% -50.0%
Total Long-Term Liabilities $46.00K $69.00K $56.00K
YoY Change 283.33% 23.21% -72.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $7.292M $6.450M $4.816M
Total Long-Term Liabilities $46.00K $69.00K $56.00K
Total Liabilities $7.338M $6.519M $4.872M
YoY Change 63.61% 33.81% -56.29%
SHAREHOLDERS EQUITY
Retained Earnings -$268.9M -$256.5M -$212.4M
YoY Change 21.17% 20.73% 28.3%
Common Stock $4.000K $4.000K $56.00K
YoY Change -92.86% -92.86% 2700.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $73.34M $84.43M $78.05M
YoY Change
Total Liabilities & Shareholders Equity $80.68M $90.95M $82.92M
YoY Change 2.6% 9.68% -12.65%

Cashflow Statement

Concept 2017 Q2 2017 Q1 2016 Q1
OPERATING ACTIVITIES
Net Income -$12.41M -$12.60M -$9.589M
YoY Change 31.04% 31.42% -35.03%
Depreciation, Depletion And Amortization $229.0K $335.0K $494.0K
YoY Change -53.27% -32.19% 68.03%
Cash From Operating Activities -$10.15M -$10.91M -$9.960M
YoY Change 15.08% 9.54% -26.28%
INVESTING ACTIVITIES
Capital Expenditures -$140.0K $274.0K $125.0K
YoY Change 250.0% 119.2% -81.45%
Acquisitions
YoY Change
Other Investing Activities $10.00K $0.00 $220.0K
YoY Change -87.5% -100.0% 266.67%
Cash From Investing Activities -$130.0K -$270.0K $90.00K
YoY Change -425.0% -400.0% -114.52%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $37.50M $4.325M
YoY Change 767.05%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -210.0K 37.83M 4.330M
YoY Change -104.66% 773.67% 2992.86%
NET CHANGE
Cash From Operating Activities -10.15M -10.91M -9.960M
Cash From Investing Activities -130.0K -270.0K 90.00K
Cash From Financing Activities -210.0K 37.83M 4.330M
Net Change In Cash -10.49M 26.65M -5.540M
YoY Change 145.67% -581.05% -60.4%
FREE CASH FLOW
Cash From Operating Activities -$10.15M -$10.91M -$9.960M
Capital Expenditures -$140.0K $274.0K $125.0K
Free Cash Flow -$10.01M -$11.18M -$10.09M
YoY Change 14.01% 10.9% -28.9%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2016Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4656000 USD
CY2017Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5085000 USD
CY2017Q1 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2017Q1 dei Entity Registrant Name
EntityRegistrantName
VITAL THERAPIES INC
CY2017Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001280776
CY2017Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
42207376 shares
CY2017Q1 dei Trading Symbol
TradingSymbol
VTL
CY2016Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
780000 USD
CY2017Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
1308000 USD
CY2017Q1 dei Amendment Flag
AmendmentFlag
false
CY2017Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2017Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2017Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2017
CY2017Q1 dei Document Period End Date
DocumentPeriodEndDate
2017-03-31
CY2017Q1 dei Document Type
DocumentType
10-Q
CY2016Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
9601000 USD
CY2017Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
9936000 USD
CY2016Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
83000 USD
CY2017Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
84000 USD
CY2016Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
302185000 USD
CY2017Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
340817000 USD
CY2016Q4 us-gaap Assets
Assets
64026000 USD
CY2017Q1 us-gaap Assets
Assets
90947000 USD
CY2016Q4 us-gaap Assets Current
AssetsCurrent
61463000 USD
CY2017Q1 us-gaap Assets Current
AssetsCurrent
88302000 USD
CY2016Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
0 USD
CY2017Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
87000 USD
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
83416000 USD
CY2016Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
77876000 USD
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
59991000 USD
CY2017Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
86636000 USD
CY2016Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-5540000 USD
CY2017Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
26645000 USD
CY2016Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2017Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2017Q1 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
5250590 shares
CY2016Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2017Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2016Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
130000000 shares
CY2017Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
130000000 shares
CY2016Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
32143475 shares
CY2017Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
42207376 shares
CY2016Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
32143475 shares
CY2017Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
42207376 shares
CY2016Q4 us-gaap Common Stock Value
CommonStockValue
3000 USD
CY2017Q1 us-gaap Common Stock Value
CommonStockValue
4000 USD
CY2016Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-9589000 USD
CY2017Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-12601000 USD
CY2016Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
44000 USD
CY2017Q1 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
57000 USD
CY2016Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
99000 USD
CY2017Q1 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
69000 USD
CY2016Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
494000 USD
CY2017Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
335000 USD
CY2016Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.31
CY2017Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.39
CY2016Q1 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations
EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations
-1000 USD
CY2017Q1 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations
EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations
0 USD
CY2016Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2154000 USD
CY2017Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1330000 USD
CY2017Q1 us-gaap Fair Value Assumptions Expected Dividend Rate
FairValueAssumptionsExpectedDividendRate
0
CY2016Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2799000 USD
CY2017Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3059000 USD
CY2016Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-361000 USD
CY2017Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
396000 USD
CY2016Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1476000 USD
CY2017Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
33000 USD
CY2016Q1 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-40000 USD
CY2017Q1 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-17000 USD
CY2016Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-18000 USD
CY2017Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
316000 USD
CY2016Q1 us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
-213000 USD
CY2017Q1 us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
0 USD
CY2016Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
60000 USD
CY2017Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
97000 USD
CY2016Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
64026000 USD
CY2017Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
90947000 USD
CY2016Q4 us-gaap Liabilities Current
LiabilitiesCurrent
5480000 USD
CY2017Q1 us-gaap Liabilities Current
LiabilitiesCurrent
6450000 USD
CY2016Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
100000 USD
CY2017Q1 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
69000 USD
CY2016Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
4327000 USD
CY2017Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
37826000 USD
CY2016Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
90000 USD
CY2017Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-271000 USD
CY2016Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-9956000 USD
CY2017Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-10910000 USD
CY2016Q1 us-gaap Net Income Loss
NetIncomeLoss
-9589000 USD
CY2017Q1 us-gaap Net Income Loss
NetIncomeLoss
-12602000 USD
CY2016Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
67000 USD
CY2017Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
85000 USD
CY2017Q1 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1 segment
CY2016Q1 us-gaap Operating Expenses
OperatingExpenses
9656000 USD
CY2017Q1 us-gaap Operating Expenses
OperatingExpenses
12687000 USD
CY2016Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-9656000 USD
CY2017Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-12687000 USD
CY2016Q1 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
217000 USD
CY2017Q1 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
255000 USD
CY2016Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
186000 USD
CY2017Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
542000 USD
CY2016Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
58000 USD
CY2017Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
156000 USD
CY2016Q1 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
0 USD
CY2017Q1 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
1000 USD
CY2016Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
44000 USD
CY2017Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
57000 USD
CY2016Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
7000 USD
CY2017Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-12000 USD
CY2016Q1 us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
0 USD
CY2017Q1 us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
-2000 USD
CY2016Q1 us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
30000 USD
CY2017Q1 us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
0 USD
CY2016Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
125000 USD
CY2017Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
274000 USD
CY2016Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2017Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2016Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2017Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2016Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2017Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2016Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2017Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2016Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2017Q1 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2016Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1472000 USD
CY2017Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1666000 USD
CY2016Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
4325000 USD
CY2017Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
37825000 USD
CY2016Q1 us-gaap Proceeds From Sale Of Machinery And Equipment
ProceedsFromSaleOfMachineryAndEquipment
2000 USD
CY2017Q1 us-gaap Proceeds From Sale Of Machinery And Equipment
ProceedsFromSaleOfMachineryAndEquipment
3000 USD
CY2016Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
32000 USD
CY2017Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1000 USD
CY2016Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
12106000 USD
CY2017Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
12425000 USD
CY2016Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2505000 USD
CY2017Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2489000 USD
CY2016Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6857000 USD
CY2017Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9628000 USD
CY2016Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-243825000 USD
CY2017Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-256477000 USD
CY2016Q1 us-gaap Share Based Compensation
ShareBasedCompensation
998000 USD
CY2017Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1263000 USD
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
3039736 shares
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
7.92
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
11579 shares
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
11.27
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
35408 shares
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
6.04
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.48
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
1414901 USD
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4841274 shares
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4863702 shares
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
7.78
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
7.76
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
1414901 USD
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
4761730 shares
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
7.77
CY2017Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.43
CY2017Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
5.05
CY2017Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P10Y
CY2017Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
1414901 USD
CY2017Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y26D
CY2017Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y1M6D
CY2017Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P7Y26D
CY2017Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
1401 shares
CY2015Q4 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
34500000 USD
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
58446000 USD
CY2017Q1 us-gaap Stockholders Equity
StockholdersEquity
84428000 USD
CY2017Q1 us-gaap Tangible Asset Impairment Charges
TangibleAssetImpairmentCharges
0 USD
CY2016Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
30563088 shares
CY2017Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
32645103 shares
CY2016Q4 vtl Accrued Clinical Costs
AccruedClinicalCosts
2316000 USD
CY2017Q1 vtl Accrued Clinical Costs
AccruedClinicalCosts
3213000 USD
CY2016Q1 vtl Change In Stock Option Early Exercise Repurchase Liability
ChangeInStockOptionEarlyExerciseRepurchaseLiability
23000 USD
CY2017Q1 vtl Change In Stock Option Early Exercise Repurchase Liability
ChangeInStockOptionEarlyExerciseRepurchaseLiability
0 USD
CY2016Q1 vtl Common Stock Issuance Costs Included In Liabilities
CommonStockIssuanceCostsIncludedInLiabilities
65000 USD
CY2017Q1 vtl Common Stock Issuance Costs Included In Liabilities
CommonStockIssuanceCostsIncludedInLiabilities
481000 USD
CY2017Q1 vtl Issuance Of Securities Authorized Offering Amount
IssuanceOfSecuritiesAuthorizedOfferingAmount
113100000 USD
CY2015Q2 vtl Issuance Of Securities Authorized Offering Amount
IssuanceOfSecuritiesAuthorizedOfferingAmount
200000000 USD
CY2015Q2 vtl Maximum Number Of Common Shares That Can Be Issued By Certain Stockholders Under Shelf Registration Statement
MaximumNumberOfCommonSharesThatCanBeIssuedByCertainStockholdersUnderShelfRegistrationStatement
2500000 shares
CY2017Q1 us-gaap Use Of Estimates
UseOfEstimates
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-top:16px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with GAAP requires us to make certain estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results could differ materially from those estimates and assumptions.</font></div></div>

Files In Submission

Name View Source Status
0001280776-17-000029-index-headers.html Edgar Link pending
0001280776-17-000029-index.html Edgar Link pending
0001280776-17-000029.txt Edgar Link pending
0001280776-17-000029-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
vtl-033117xexhibit1018.htm Edgar Link pending
vtl-033117xexhibit311.htm Edgar Link pending
vtl-033117xexhibit312.htm Edgar Link pending
vtl-033117xexhibit321.htm Edgar Link pending
vtl-033117xexhibit322.htm Edgar Link pending
vtl-20170331.xml Edgar Link completed
vtl-20170331.xsd Edgar Link pending
vtl-20170331_cal.xml Edgar Link unprocessable
vtl-20170331_def.xml Edgar Link unprocessable
vtl-20170331_lab.xml Edgar Link unprocessable
vtl-20170331_pre.xml Edgar Link unprocessable
vtl-33117x10q.htm Edgar Link pending